Scientific Reference
Cerebrolysin
Evidence profile: Preclinical, with limited uncontrolled human reports
Cerebrolysin is a standardised neuropeptide preparation derived from purified porcine brain proteins, containing low-molecular-weight peptides and free amino acids. It is formulated to resemble endogenous neurotrophic factors, and the published literature examines it in the context of neuronal survival and plasticity. Study outcomes across the literature remain mixed. It is of porcine origin. Cerebrolysin is not an approved medicine in the United Kingdom. Supplied strictly as a research compound for laboratory use.
Published Research
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series
Vester JC et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021 · Review
PMID 33620612 — View on PubMedCerebrolysin for acute ischaemic stroke
Ziganshina LE et al. · The Cochrane database of systematic reviews · 2020 · Review
PMID 32662068 — View on PubMedCerebrolysin for vascular dementia
Cui S et al. · The Cochrane database of systematic reviews · 2019 · Review
PMID 31710397 — View on PubMedCerebrolysin for acute ischaemic stroke
Ziganshina LE et al. · The Cochrane database of systematic reviews · 2017 · Review
PMID 28430363 — View on PubMedCerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials
Wang Z et al. · Drug design, development and therapy · 2017 · Review
PMID 28458521 — View on PubMedCerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Gauthier S et al. · Dementia and geriatric cognitive disorders · 2015 · Review
PMID 25832905 — View on PubMed